Drugs / Meglumine antimonate
Meglumine antimonate
also known as
Meglumine Antimoniate · Glucantime · Glucantim · Glucantime (meglumine antimoniate) · N-methylglucamine antimonate
Trials 11
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT01050777 | Mar 2011 → Jan 2012 | cutaneous leishmaniasis | Tehran University of Medical Sciences | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT07652021 | Aug 2026 → Feb 2027 expected | cutaneous leishmaniasis | Combined military hospital Peshawar | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT02530697 | Aug 2015 → Aug 2025 overdue | leishmaniasis | University of Brasilia | Active not recruiting | No outcome recorded |
| Phase 2 | NCT01380301 | Mar 2007 → Aug 2008 | cutaneous leishmaniasis | Foundation Fader | Terminated | No outcome recorded |
| Phase 2 | NCT00004755 | Sep 1995 → ? | leishmaniasis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT00537953 | — | cutaneous leishmaniasis | Centro de Investigaciones Bioclínicas de la Fundación Fader | Unknown | No outcome recorded |
| Phase 2/32 trials · 1 missed | ||||||
| Phase 2/3 | NCT06011343 | Oct 2023 → Oct 2024 | cutaneous leishmaniasis | Hospital Universitário Professor Edgard Santos | Unknown | No outcome recorded |
| Phase 2/3 | NCT01301924 | Oct 2008 → Apr 2016 | cutaneous leishmaniasis | Oswaldo Cruz Foundation | Completed | Missed primary |
| Phase 32 trials | ||||||
| Phase 3 | NCT04515186 | Jan 2021 → Nov 2023 | cutaneous leishmaniasis | Drugs for Neglected Diseases | Completed | No outcome recorded |
| Phase 3 | NCT04340128 | May → Oct 2007 | cutaneous leishmaniasis | Tehran University of Medical Sciences | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT00818818 | Aug 2008 → Jan 2010 | cutaneous leishmaniasis | University of Brasilia | Completed | No outcome recorded |
| Comparator or background therapy18 trials | ||||||
| Phase 1/2 | NCT06000514 Background | Jan 2019 → Apr 2022 | cutaneous leishmaniasis | Hospital Universitário Professor Edgard Santos | Completed | No outcome recorded |
| Phase 2 | NCT03084952 Comparator | May 2021 → Dec 2023 | cutaneous leishmaniasis, drug-induced mental disorder | Infan Industria Quimica Farmaceutica Nacional | Unknown | No outcome recorded |
| Phase 2 | NCT03294161 Comparator | Dec 2014 → Apr 2017 | cutaneous leishmaniasis | Hospital Universitário Professor Edgard Santos | Completed | No outcome recorded |
| Phase 2 | NCT01377974 Comparator | Jul 2009 → Jun 2013 | mucocutaneous leishmaniasis | Brasilia University Hospital | Completed | No outcome recorded |
| Phase 2 | NCT00600548 Comparator | Jul 2007 → Mar 2009 | cutaneous leishmaniasis | Hospital Universitário Professor Edgard Santos | Completed | Met primary |
| Phase 2 | NCT00973128 Comparator | Feb 2004 → Oct 2006 | cutaneous leishmaniasis | Hospital Universitário Professor Edgard Santos | Completed | No outcome recorded |
| Phase 2/3 | NCT01464242 Background | Nov 2011 → Jan 2015 | cutaneous leishmaniasis | International Center for Training and Medical Research | Completed | No outcome recorded |
| Phase 2/3 | NCT01301937 Comparator | Oct 2008 → Dec 2020 | mucocutaneous leishmaniasis | Oswaldo Cruz Foundation | Unknown | No outcome recorded |
| Phase 2/3 | NCT00682656 Comparator | Jun 2008 → Dec 2011 | cutaneous leishmaniasis | Ana Rabello | Terminated | No outcome recorded |
| Phase 3 | NCT06822478 Comparator | Mar 2026 → Dec 2029 expected | cutaneous leishmaniasis | Universidad de Antioquia | Recruiting | No outcome recorded |
| Phase 3 | NCT04799236 Comparator | Apr 2021 → Apr 2024 | mucocutaneous leishmaniasis | Fundacion Nacional de Dermatologia | Unknown | No outcome recorded |
| Phase 3 | NCT01953744 Comparator | Feb 2014 → Apr 2015 | cutaneous leishmaniasis | Hospital Universitário Professor Edgard Santos | Terminated | Missed primary |
| Phase 3 | NCT00487253 Comparator | Jul 2007 → Feb 2010 | cutaneous leishmaniasis | International Center for Training and Medical Research | Unknown | No outcome recorded |
| Phase 3 | NCT00471705 Comparator | Jun 2006 → Aug 2008 | cutaneous leishmaniasis | Universidad de Antioquia | Completed | Missed primary |
| Phase 3 | NCT00317629 Comparator | May 2006 → Jan 2009 | cutaneous leishmaniasis | Fundación Cardiovascular de Colombia | Terminated | No outcome recorded |
| Phase 4 | NCT01032187 Comparator | Oct 2007 → Jan 2010 | visceral leishmaniasis | University of Brasilia | Completed | No outcome recorded |
| Phase 4 | NCT00317980 Comparator | Feb 2006 → Mar 2008 | cutaneous leishmaniasis | University of Brasilia | Completed | No outcome recorded |
| — | NCT00480883 Comparator | Jan → Jun 2008 | cutaneous leishmaniasis | Combined Military Hospital, Pakistan | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 30 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Meglumine antimonate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01464242 ↗ |
| Known as | Glucantim | ChEMBL registry synonym — accepted as the source's own label CHEMBL239129 ↗ |
| Known as | Glucantime | “Intralesional meglumine antimoniate (Glucantime) administered according to the study protocol for treatment of cutaneous leishmaniasis.” NCT07652021 ↗6“Nano-liposomal Meglumine Antimoniate (Glucantime)” NCT01050777 ↗ “meglumine antimoniate (Glucantime)” NCT06011343 ↗ |
| Known as | Glucantime (meglumine antimoniate) | “Glucantime® (meglumine antimoniate)” NCT00471705 ↗ |
| Known as | Meglumine Antimoniate | “Miltefosine 1,5 to 2,5 mg x k x d during 14 days simultaneously with meglumine antimoniate 20 mg x kg x d during 10 days” NCT01380301 ↗23“IV pentavalent antimony (meglumine antimoniate) will be administrated at 20 mg x kg x d during 20 consecutive days.” NCT04799236 ↗ “Meglumine antimoniate (MA) is the first-choice drug for the treatment of CL” PMID 39147194 ↗ Aug 2024 |
| Known as | N-methylglucamine antimonate | ChEMBL registry synonym — accepted as the source's own label CHEMBL239129 ↗ |
| Modality | Other / unclassified | “pentavalent antimonials (sodium stibogluconate and meglumine antimoniate)” NCT04340128 ↗ |
| Route | Intramuscular | “daily intramuscular injections of glucantime” NCT00004755 ↗ |